Figure 4
FISH on metaphase chromosomes. (a) Hybridization with the HHV-6-specific biotinylated probe showed a single site of HHV-6 integration with symmetrical doublet signals at homologous sites of both chromatids of chromosome 1 (arrow). An arrowhead indicates the Ph 
Fulminant hepatosplenic B cell lymphoma in a young patient with HCV-chronic hepatitis

TO THE EDITOR
A high prevalence of hepatitis C virus (HCV) infection has recently been described in patients with B cell non-Hodgkin lymphomas (NHL). [1] [2] [3] [4] On the other hand, we have not found any definitive report regarding the incidence rate of overt NHL in large cohorts of HCV-infected patients. 5 Specific clinical and histopathological characteristics in HCV-related lymphomas need to be defined. Significant differences have been reported in HCV genotypes. 2, 3 The histological spectrum of HCV-related NHL appears to be wide, lymphoplasmocytoid lymphoma, diffuse large B cell lymphoma and monocytoid B cell lymphoma emerging as the most common subtypes. [2] [3] [4] Extranodal primary involvement of the liver and/or spleen has been shown to be more frequent in HCV-infected patients 1, 3 compared with those uninfected. 3 So far, immunophenotypic and/or molecular characteristics have not been described in detail.
We report here the case of a 37-year-old Caucasian man, (PROMACE/cytaBON protocol) .
The patient died 24 h after the chemotherapy was initiated, on the 13th hospital day. The autopsy showed large confluent nodules in spleen and liver, as well as local retroperitoneal lymph nodes, bilateral adrenal and bone marrow neoplastic involvement. Strikingly, there were no additional sites. Flow cytometry of a cellular suspension obtained from one of the hepatic nodules showed CD19 + CD20 + CD22 + sKappa + HLA-DR + CD45RA + cells, with no expression of CD5, CD34, CD10, CD103, CD56, CD122 or CD3. The tumor was classified as a diffuse large B cell lymphoma (REAL classification).
Clinicians should consider that the spectrum of HCV-related B cell clonal expansions may include high-grade lymphomas, with fulminant presentations in young patients like the one reported here; an uncommon event in the series reported so far. Further clinical, pathological and epidemiological studies are needed to assess the impact of B cell malignancies complicating the course of HCV infection and to set the guidelines for the appropriate surveillance in HVC-infected patients. It is
Late relapse in BCR/ABL-positive patients after non-intensive chemotherapy
TO THE EDITOR
The recent study by Brisco et al 1 shows that cases of Philadelphia (Ph) chromosome positive and negative adult acute lymphoblastic leukemia (ALL) can initially have similar drug resistance, determined by the degree of minimum residual disease (MRD) at the end of induction. In turn, another recent study Preudhomme et al 2 showed the importance of followup by RT-PCR of the BCR/ABL hybrid gene derived from t(9;22) that gives rise to the Ph chromosome, in predicting the outcome of these patients. However, other authors have described patients not submitted to allogeneic bone marrow transplantation as having a persistently positive BCR/ABL in prolonged complete hematologic remission (CR). 3 We present two cases of tardy relapsed BCR/ABL-positive ALL after conventional chemotherapy treatment indicating that when CR is achieved in these patients they can relapse much later on. This finding must be taken into account in the assessment of MRD studies.
Case 1
A 37-year-old woman was diagnosed on 16 February 1990 with precursor B cell ALL (CD10 + , CD19 + , HLADR + ), WBC 4.7 × 10 9 /l. The cytogenetic analysis was inconclusive because of insufficient samples. The patient was treated according to the German multicentric trial chemotherapeutic protocol adult ALL 03/87 of high risk 4 (due to age). Complete hematologic remission was achieved after induction and the treatment finished on 28 December 1992. From this moment she remained in CR until 9 February 1997 (96 months after the diagnosis, 95 months after achieving CR and 45.5 months after completing treatment) when she was diagnosed with relapsed B cell precursor ALL (CD10 
